B
Baker Bros. Advisors LP
+ HältFTH
+20.53%
3-Monats-Rendite
$18.690
-0.060 (-0.32%)Zum Schluss
Loading chart…
- Hoch
- 19.040
- Eröffnung
- 18.560
- Volumengewichteter Durchschnittskurs
- 18.54
- Volumen
- 510.97K
- Marktkap.
- —
- Tief
- 17.880
- Umsatz
- 9.47M
- EV/EBITDA, TTM
- 0.00
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
KI-Analyse of Faeth Therapeutics, Inc (FTH)
KaufenFaeth Therapeutics is a good buy right now due to its current price of $17.08, which is significantly below analyst price targets, with Guggenheim setting a target of $70. The stock's RSI is at 20.185, indicating it is oversold and may be due for a rebound. However, the main risk is the negative earnings trend, with a recent EPS of -2.84, which reflects ongoing losses that could impact investor sentiment.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Faeth Therapeutics, Inc (FTH) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .
Whales, die FTH halten
Event-Zeitleiste
News
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
9.010-23NewsfilterFaeth Therapeutics Presents PIKTOR Clinical Data at ESMO 2026
- 8.510-19Newsfilter
Faeth Therapeutics Presents Efficacy Data for PIKTOR at ESMO Congress 2026
6.009-09CNBCLatest Ratings and Price Target Adjustments on Wall Street
- 8.509-08Newsfilter
Faeth Therapeutics to Host KOL Event on Cancer Therapy Insights
FTH FAQ – beantwortet von Alphio AI
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib. It operates in the Healthcare sector.
Faeth Therapeutics is a good buy right now due to its current price of $17.08, which is significantly below analyst price targets, with Guggenheim setting a target of $70. The stock's RSI is at 20.185, indicating it is oversold and may be due for a rebound. However, the main risk is the negative earnings trend, with a recent EPS of -2.84, which reflects ongoing losses that could impact investor sentiment.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.